Moleculin Biotech Inc (MBRX.OQ)
8 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA
- BRIEF-Moleculin Biotech Q3 loss per share $0.14
- BRIEF-Moleculin appoints Sandra Silberman as chief medical officer
- BRIEF-Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors
- BRIEF-Moleculin requests for clinical trial authorization to study annamycin